Below are IPR updates from this week.
On December 13, 2017, the Board instituted two IPRs on Mylan’s petitions (IPR2017-01526 and IPR2017-01528) challenging Sanofi’s U.S. Patent Nos. 7,713,930 and 7,476,652, respectively, both related to insulin glargine. As we have reported, both patents are the subject of litigation pending in the District of Delaware: Sanofi-Aventis U.S. v. Merck Sharpe and Dohme Corp., No. 16-00812.
On December 14, 2017, Pfizer filed a petition challenging Biogen’s U.S. Patent No. 8,329,172 (“the ‘172 patent”)(IPR2018-00285). The ‘172 patent is directed to methods of treating low-grade non-Hodgkin’s lymphoma. This is the second IPR petition Pfizer has filed challenging the ‘172 patent. As we reported here, institution of Pfizer’s first petition (IPR2017-01166), filed on April 21, 2017, was denied on November 13, 2017.